Provision of a Chemotherapy ePrescribing System and Support Services

Tender description

Provision of a Chemotherapy ePrescribing System and Support Services for and on behalf of (1) Imperial College Healthcare NHS Trust, (2) Chelsea and Westminster Hospital NHS Foundation Trust, (3) London North West University Healthcare NHS Trust and (4) The Hillingdon Hospitals NHS Foundation Trust Lot 1: Imperial College Healthcare NHS Trust, acting as lead Authority for (1) Imperial College Healthcare NHS Trust, (2) Chelsea and Westminster Hospital NHS Foundation Trust, (3) London North West University Healthcare NHS Trust and (4) The Hillingdon Hospitals NHS Foundation Trust, requires a single, specialist Chemotherapy Electronic Prescribing System for cancer services for use across the North West London (NWL) Integrated Care System (ICS).The solution needs to have the capability of interfacing with numerous IT systems within each participating Trust to provide both clinical and administrative functions, with the ability to support services that are located across multiple sites, both in acute and community/outpatient settings.The supplier will be contracted for the supply and maintenance of a Chemotherapy Electronic Prescribing System which must include Haemato-oncology, Solid Tumours and Paediatric Oncology.The successful solution must provide the following key functionality: 1. Provision of specialist chemotherapy e-Prescribing providing a complete end-to-end chemotherapy prescribing solution including predefined regimens, prescribing, scheduling, dispensing, through to chemotherapy administration and reporting. 2. The ability to integrate with other software solutions both internal and external to the participating NWL ICS Trusts. In particular, with the increasing integration of cytotoxic treatment and radiotherapy, integrate with radiotherapy treatment and verification systems to support chemo-radiation regimens. The integration must be capable of two-way communication with other Trust solutions ensuring critical clinical information is shared. 3. The ability to accommodate all of the participating NWL ICS Trust’s cancer patients for the duration of the contract including any possible future service expansion requirements. Automatic dose calculations, allergy & sensitivity alerting, decision support linked to pathology & toxicity, drug-to-drug interaction support, and bar-coded wristband & drug scanning. 4. Enable the participating NWL ICS Trusts to analyse and audit all clinical processes of all participating Trusts chemotherapy prescribing activities and be fully compliant with all national reporting requirements including SACT (NHS Standards - Appendix 2) 5. The successful solution must provide integration capability to integrate with each participating NWL ICS Trusts pre-defined application currently in use, as part of in-flight projects and new projects. The main term of the contract shall be 5 years with the option, at the Authority's sole discretion, for 2 + 2 + 1 year contract extensions.